![](https://i0.wp.com/instanosis.com/wp-content/uploads/2023/10/dreamstime_xxl_123521852-scaled.jpg?resize=2560%2C1707&ssl=1)
News
May 17, 2024:
Instanosis published a new research paper on a novel chemiluminescence assay for the rapid and sensitive detection of fentanyl. The work is done through a multi-institutional collaboration including Instanosis Inc., the University of Pennsylvania, Mayo Clinic, and ATGC Inc.
April 15, 2024:
Instanosis announces the FDA clearance of InstaStrip Fentanyl. The product is a dipstick test for the qualitative detection of Fentanyl in human urine. InstaStrip Fentanyl is both CLIA-Waived and OTC compliant. The kit detect Fentanyl in human urine at a cutoff of 1 ng/mL.
March 18, 2024:
Instanosis has been awarded a new NIH Blue Print Medtech Small Business Translator SBIR grant for developing a rapid urine xylazine test device.
March 18, 2024:
Instanosis has been awarded a new NIH fast track SBIR grant for developing a rapid urine fentanyl test device.
October 24, 2023:
Instanosis’s InstaStrip-Fentanyl Rapid Test has been granted Breakthrough Device designation by the United States Food and Drug Administration (FDA).
June 20, 2023:
Instanosis has successfully implemented Quality Management System, compliant with FDA requirements
June 16, 2023:
Instanosis is awarded a Small Business Innovation Research grant supplement from the NIH to develop lateral flow assays for rapid fentanyl detection
June 06, 2023:
Instanosis is awarded a Small Business Technology Transfer Grant from the NIH to use smartphones to reduce prostate cancer monitoring disparities
August 22, 2022:
Instanosis is awarded a Small Business Innovation Research Grant from the NIH to develop lateral flow assays for rapid fentanyl detection